Benitec Biopharma Reports Director Changes and Shareholder Votes
Ticker: BNTC · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1808898
Sentiment: neutral
Topics: corporate-governance, director-changes, shareholder-vote
TL;DR
Benitec Biopharma's 8-K shows director shakeups and votes - governance changes afoot.
AI Summary
Benitec Biopharma Inc. filed an 8-K on August 29, 2024, reporting on the departure of directors, election of new directors, and compensatory arrangements. The filing also covers matters submitted to a vote of security holders and includes financial statements and exhibits. The company is incorporated in Delaware and headquartered in Hayward, California.
Why It Matters
This filing indicates significant corporate governance changes and potential shareholder actions, which could impact the company's strategic direction and investor relations.
Risk Assessment
Risk Level: medium — Changes in board composition and shareholder votes can signal underlying issues or strategic shifts that may affect the company's future performance.
Key Players & Entities
- Benitec Biopharma Inc. (company) — Registrant
- August 29, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Hayward, California (location) — Address of Principal Executive Offices
FAQ
What specific director departures were reported?
The filing indicates the 'Departure of Directors or Certain Officers' as an item of information, but does not list specific names in the provided text.
Who were the newly elected directors?
The filing mentions the 'Election of Directors' as an item of information, but specific names are not detailed in the provided text.
What compensatory arrangements were disclosed?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the specifics are not included in the provided text.
What matters were submitted to a vote of security holders?
The filing states 'Submission of Matters to a Vote of Security Holders' as an item, but the details of these matters are not provided.
When was the earliest event reported in this 8-K?
The earliest event reported in this 8-K was on August 29, 2024.
Filing Stats: 777 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2024-09-04 20:37:17
Key Financial Figures
- $0.0001 B — ich registered Common Stock, par value $0.0001 BNTC The Nasdaq Stock Market LLC Indic
Filing Documents
- d868099d8k.htm (8-K) — 32KB
- 0001193125-24-213348.txt ( ) — 149KB
- bntc-20240829.xsd (EX-101.SCH) — 3KB
- bntc-20240829_lab.xml (EX-101.LAB) — 17KB
- bntc-20240829_pre.xml (EX-101.PRE) — 11KB
- d868099d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Third Amendment to Benitec Biopharma Inc. 2020 Equity and Incentive Compensation Plan, dated as of August 29, 2024 (incorporated by reference to Annex A to the Company's Definitive Proxy Statement on Schedule 14A filed on July 29, 2024). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BENITEC BIOPHARMA INC. Date: September 4, 2024 By: /s/ Jerel A. Banks Name: Jerel A. Banks Title: Chief Executive Officer